ArticleClinical Medicine Insights. Oncology2026
Integrative Analysis of Clinical Features and Cerebrospinal Fluid Immune Microenvironment in Leptomeningeal Metastasis From Non-small-cell Lung Cancer Patients.
Article in Clinical Medicine Insights. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leptomeningeal metastasis (LM) represents one of the most severe complications in advanced lung cancer, indicating a poor prognosis. However, the mechanisms underlying LM progression remain incompletely understood, and reliable biomarkers for monitoring disease progression and treatment response are lacking. Methods: This retrospective observational study was conducted at the Zhejiang Provincial People's Hospital. Cerebrospinal fluid (CSF) samples from 13 patients with non-small cell lung cancer (NSCLC) and LM were analyzed, including biochemical parameters, tumor markers, differential cell counts, and T-cell subsets assessed by flow cytometry. Results: The median overall survival (mOS) after LM diagnosis was 15 months. During LM progression, increased CSF levels of albumin, lactate dehydrogenase (LDH), lactic acid, and carcinoembryonic antigen (CEA) were observed, accompanied by decreased glucose, chloride, lymphocyte proportion, and CD8 Conclusions: These findings suggest that CSF biochemical and immune parameters may be associated with disease progression in LM. Dynamic changes in CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.